editorial stem cells for cartilage regeneration: a...

3
Editorial Stem Cells for Cartilage Regeneration: A Roadmap to the Clinic Celeste Scotti , 1 Alberto Gobbi, 2 Norimasa Nakamura , 3,4 and Giuseppe M. Peretti 5,6 1 Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland 2 Orthopaedic Arthroscopic Surgery International (OASI) Bioresearch Foundation, Gobbi Onlus, Milan, Italy 3 Institute for Medical Science in Sports, Osaka Health Science University, Osaka, Japan 4 Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan 5 IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy 6 Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Correspondence should be addressed to Celeste Scotti; [email protected] Received 11 March 2018; Accepted 11 March 2018; Published 11 April 2018 Copyright © 2018 Celeste Scotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cell therapies for cartilage repair date back to 1987 when the rst autologous chondrocyte implantation (ACI) procedure was performed. Since then, more than 30,000 patients have been treated with these techniques, which should not be considered experimentalanymore. Over the years, several technical improvements have been implemented, leading to incremental advances in the surgical procedure, as reviewed by Y. Nam et al. However, a predictable, standardized, and durable regeneration of hyaline cartilage tissue, capable to withstand the mechanical forces acting in the joint and to prevent joint degeneration, remains an unmet medical need [1]. In this special issue entitled Stem Cells for Cartilage Regeneration: A Roadmap to the Clinic,the authors addressed several relevant topics, ranging from advanced in vitro and in vivo models to alternative cell sources, including induced pluripotent stem cells (iPS), and from smart materials to additional target tissues with high unmet medical need, such as the trachea or the temporomandibular joint (TMJ). A key bottleneck to improved therapies is represented by reliable in vitro and in vivo models, capable to predict the clinical outcome. Strong advances have been made in this eld, towards the development of high-throughput systems that allows testing multiple conditions with reproducible, quick, and aordable methods, and S. Lopa et al. provided a comprehensive review of microuidics and bioprinting applications. Another important topic is quality control in cell therapies, in order to better standardize the clinical outcome. K. Shiraishi et al. reported an interesting study analysis of mRNA and miRNA correlated with in vivo cartilage repair, which may open new avenues for patient stratication and selection, beyond the mere quality control. Regarding in vivo models, a translational model capable to duplicate the challenging clinical scenarios has yet to be developed. M. Lo Monaco et al. reviewed extensively this topic, ranging from small to large animal models and providing critical insights for study planning. The use of articular chondrocytes as a cell source has been considered a bottleneck to a more robust and repro- ducible regeneration of the articular surface, because of their typical age-dependency and interdonor variability in the cartilage-forming capacity [2]. For this reason, recent research focused on alternative cell sources and experimen- tal models in order to overcome the intrinsic limitations of autologous cell therapies based on articular chondrocytes. J. N. Fisher et al. reviewed recent advances in preclinical and clinical research on a number of tissue sources of pro- genitor cells for cartilage repair, highlighting pros and cons of each of them, with a focus on the potential for clinical translation. K. D. Jorgenson et al. presented a suspension bioreactor incorporating microcarrier technology for the ecient culture of synovial uid-derived MSCs, which can potentially support further research with this cell source. Infrapatellar fat pad-derived cells gained attention because of their easy accessibility and chondrogenic potential. Hindawi Stem Cells International Volume 2018, Article ID 7348560, 2 pages https://doi.org/10.1155/2018/7348560

Upload: others

Post on 24-Jul-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Editorial Stem Cells for Cartilage Regeneration: A …downloads.hindawi.com/journals/sci/2018/7348560.pdfEditorial Stem Cells for Cartilage Regeneration: A Roadmap to the Clinic Celeste

EditorialStem Cells for Cartilage Regeneration: A Roadmap to the Clinic

Celeste Scotti ,1 Alberto Gobbi,2 Norimasa Nakamura ,3,4 and Giuseppe M. Peretti 5,6

1Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland2Orthopaedic Arthroscopic Surgery International (OASI) Bioresearch Foundation, Gobbi Onlus, Milan, Italy3Institute for Medical Science in Sports, Osaka Health Science University, Osaka, Japan4Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan5IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy6Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

Correspondence should be addressed to Celeste Scotti; [email protected]

Received 11 March 2018; Accepted 11 March 2018; Published 11 April 2018

Copyright © 2018 Celeste Scotti et al. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cell therapies for cartilage repair date back to 1987 when thefirst autologous chondrocyte implantation (ACI) procedurewas performed. Since then, more than 30,000 patients havebeen treated with these techniques, which should not beconsidered “experimental” anymore. Over the years, severaltechnical improvements have been implemented, leading toincremental advances in the surgical procedure, as reviewedby Y. Nam et al. However, a predictable, standardized, anddurable regeneration of hyaline cartilage tissue, capable towithstand the mechanical forces acting in the joint andto prevent joint degeneration, remains an unmet medicalneed [1].

In this special issue entitled “Stem Cells for CartilageRegeneration: A Roadmap to the Clinic,” the authorsaddressed several relevant topics, ranging from advancedin vitro and in vivo models to alternative cell sources,including induced pluripotent stem cells (iPS), and fromsmart materials to additional target tissues with high unmetmedical need, such as the trachea or the temporomandibularjoint (TMJ).

A key bottleneck to improved therapies is represented byreliable in vitro and in vivo models, capable to predict theclinical outcome. Strong advances have been made in thisfield, towards the development of high-throughput systemsthat allows testing multiple conditions with reproducible,quick, and affordable methods, and S. Lopa et al. provided acomprehensive review of microfluidics and bioprintingapplications. Another important topic is quality control in

cell therapies, in order to better standardize the clinicaloutcome. K. Shiraishi et al. reported an interesting studyanalysis of mRNA and miRNA correlated with in vivocartilage repair, which may open new avenues for patientstratification and selection, beyond the mere qualitycontrol. Regarding in vivo models, a translational modelcapable to duplicate the challenging clinical scenarios hasyet to be developed. M. LoMonaco et al. reviewed extensivelythis topic, ranging from small to large animal models andproviding critical insights for study planning.

The use of articular chondrocytes as a cell source hasbeen considered a bottleneck to a more robust and repro-ducible regeneration of the articular surface, because oftheir typical age-dependency and interdonor variability inthe cartilage-forming capacity [2]. For this reason, recentresearch focused on alternative cell sources and experimen-tal models in order to overcome the intrinsic limitations ofautologous cell therapies based on articular chondrocytes.J. N. Fisher et al. reviewed recent advances in preclinicaland clinical research on a number of tissue sources of pro-genitor cells for cartilage repair, highlighting pros and consof each of them, with a focus on the potential for clinicaltranslation. K. D. Jorgenson et al. presented a suspensionbioreactor incorporating microcarrier technology for theefficient culture of synovial fluid-derived MSCs, which canpotentially support further research with this cell source.Infrapatellar fat pad-derived cells gained attention becauseof their easy accessibility and chondrogenic potential.

HindawiStem Cells InternationalVolume 2018, Article ID 7348560, 2 pageshttps://doi.org/10.1155/2018/7348560

Page 2: Editorial Stem Cells for Cartilage Regeneration: A …downloads.hindawi.com/journals/sci/2018/7348560.pdfEditorial Stem Cells for Cartilage Regeneration: A Roadmap to the Clinic Celeste

J. F. C. do Amaral et al. reviewed the potential of infrapatellarfat pad cells, discussing their potential for cartilage repair andthe ontogeny relationship with other joint-derived cells andconcluding with some perspective for translational trialsusing this cell source. Another cell type that showedpromising preclinical data, with also a clinical trial ongoing,is synovial MSC [3]. Y. Ikeda et al. reported a successfulapproach to improve further the chondrogenic activity ofsynovial MSC, without the upregulation of hypertrophicand osteogenic genes, by enhanced IGF-1 expression. Last,human-induced pluripotent stem cells (hiPSCs) gained a lotof attention in the last decade, representing a new hope forseveral life-threatening and incurable diseases. Y. A. Rimet al. reported a relevant analysis of the chondrogenicpotential among hiPSCs from different tissues: the findingthat cord blood mononuclear cells represent a better sourcemay support further research in this direction.

Biomaterials are a mainstay of regenerative medicine,especially for articular cartilage. However, it is still a matterof controversy whether a scaffold is strictly needed or not.In this special issue, both approaches are reported. Interest-ingly, F. Hached et al. reported the positive impact of apolysaccharide hydrogel on encapsulated MSCs, with respectto cell viability and ability to secrete potentially therapeuticfactors. Regarding scaffold-free approaches, M. P. Stuartet al. reported a valuable method to engineer spheroids byusing a micromolded nonadhesive hydrogel, without theuse of growth factors.

In this special issue, the authors addressed a series oftopics of relevance for the successful translation of preclinicalapproaches. Cell sources, biomaterials, animal models, andcell manufacturing are all critical factors for cartilage repair,which require additional work to pave the way to the nextgeneration of regenerative therapies, possibly capable torestore durably both joint surface and function in patientsin need.

Celeste ScottiAlberto Gobbi

Norimasa NakamuraGiuseppe M. Peretti

References

[1] C. Scotti, A. Gobbi, G. Karnatzikos et al., “Cartilage repair in theinflamed joint: considerations for biological augmentationtoward tissue regeneration,” Tissue Engineering Part B, Reviews,vol. 22, no. 2, pp. 149–159, 2016.

[2] K. Pelttari, B. Pippenger, M. Mumme et al., “Adult humanneural crest-derived cells for articular cartilage repair,” ScienceTranslation Medicine, vol. 6, no. 251, article 251ra119, 2014.

[3] K. Shimomura, W. Ando, Y. Moriguchi et al., “Next generationmesenchymal stem cell (MSC)–based cartilage repair usingscaffold-free tissue engineered constructs generated with syno-vial mesenchymal stem cells,” Cartilage, vol. 6, Supplement 2,pp. 13S–29S, 2015.

2 Stem Cells International

Page 3: Editorial Stem Cells for Cartilage Regeneration: A …downloads.hindawi.com/journals/sci/2018/7348560.pdfEditorial Stem Cells for Cartilage Regeneration: A Roadmap to the Clinic Celeste

Hindawiwww.hindawi.com

International Journal of

Volume 2018

Zoology

Hindawiwww.hindawi.com Volume 2018

Anatomy Research International

PeptidesInternational Journal of

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Journal of Parasitology Research

GenomicsInternational Journal of

Hindawiwww.hindawi.com Volume 2018

Hindawi Publishing Corporation http://www.hindawi.com Volume 2013Hindawiwww.hindawi.com

The Scientific World Journal

Volume 2018

Hindawiwww.hindawi.com Volume 2018

BioinformaticsAdvances in

Marine BiologyJournal of

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Neuroscience Journal

Hindawiwww.hindawi.com Volume 2018

BioMed Research International

Cell BiologyInternational Journal of

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Biochemistry Research International

ArchaeaHindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Genetics Research International

Hindawiwww.hindawi.com Volume 2018

Advances in

Virolog y Stem Cells International

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Enzyme Research

Hindawiwww.hindawi.com Volume 2018

International Journal of

MicrobiologyHindawiwww.hindawi.com

Nucleic AcidsJournal of

Volume 2018

Submit your manuscripts atwww.hindawi.com